Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 ...
One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the ...
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
According to a sneak peek of the data from one of Eli Lilly's (NYSE: LLY) late-stage clinical trials, the cardiometabolic medicine juggernaut now looks even stronger in comparison to its similarly ...
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...
Patients self-administer the drug using a pre-dosed injector pen, but Lilly recently introduced the product in single-dose ...
A preliminary study on popular weight loss drugs finds participants shed more weight on Zepbound than on Novo Nordisk’s ...
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...
The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...
Lilly announced in April that it agreed to acquire the manufacturing facility from Nexus Pharmaceuticals LLC. The acquisition ...
The top China executive of US pharmaceutical company Eli Lilly and Co said on Wednesday that the company aims to make its ...